vs

Side-by-side financial comparison of INTEGRA LIFESCIENCES HOLDINGS CORP (IART) and Rackspace Technology, Inc. (RXT). Click either name above to swap in a different company.

Rackspace Technology, Inc. is the larger business by last-quarter revenue ($682.8M vs $434.9M, roughly 1.6× INTEGRA LIFESCIENCES HOLDINGS CORP). On growth, Rackspace Technology, Inc. posted the faster year-over-year revenue change (-0.4% vs -1.7%). Rackspace Technology, Inc. produced more free cash flow last quarter ($56.0M vs $-5.4M). Over the past eight quarters, INTEGRA LIFESCIENCES HOLDINGS CORP's revenue compounded faster (8.6% CAGR vs -0.6%).

Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.

Rackspace Technology, Inc. is an American cloud computing company based in San Antonio, Texas. It also has offices in Reston, Virginia, as well as in Australia, Canada, United Kingdom, India, Dubai, Switzerland, the Netherlands, Germany, Singapore, Mexico, Toronto and Hong Kong. Its data centers are located in Amsterdam (Netherlands), Virginia (USA), Chicago (USA), Dallas (USA), London (UK), Frankfurt (Germany), Hong Kong (China), Kansas City (USA), New York City (USA), San Jose (USA), Shangh...

IART vs RXT — Head-to-Head

Bigger by revenue
RXT
RXT
1.6× larger
RXT
$682.8M
$434.9M
IART
Growing faster (revenue YoY)
RXT
RXT
+1.3% gap
RXT
-0.4%
-1.7%
IART
More free cash flow
RXT
RXT
$61.4M more FCF
RXT
$56.0M
$-5.4M
IART
Faster 2-yr revenue CAGR
IART
IART
Annualised
IART
8.6%
-0.6%
RXT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IART
IART
RXT
RXT
Revenue
$434.9M
$682.8M
Net Profit
$-32.7M
Gross Margin
50.8%
17.6%
Operating Margin
5.3%
-0.5%
Net Margin
-4.8%
Revenue YoY
-1.7%
-0.4%
Net Profit YoY
41.6%
EPS (diluted)
$-0.03
$-0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IART
IART
RXT
RXT
Q4 25
$434.9M
$682.8M
Q3 25
$402.1M
$671.2M
Q2 25
$415.6M
$666.3M
Q1 25
$382.7M
$665.4M
Q4 24
$442.6M
$685.6M
Q3 24
$380.8M
$675.8M
Q2 24
$418.2M
$684.9M
Q1 24
$368.9M
$690.8M
Net Profit
IART
IART
RXT
RXT
Q4 25
$-32.7M
Q3 25
$-5.4M
$-67.1M
Q2 25
$-484.1M
$-54.5M
Q1 25
$-25.3M
$-71.5M
Q4 24
$-56.0M
Q3 24
$-10.7M
$-186.6M
Q2 24
$-12.4M
$25.0M
Q1 24
$-3.3M
$-640.6M
Gross Margin
IART
IART
RXT
RXT
Q4 25
50.8%
17.6%
Q3 25
51.5%
19.4%
Q2 25
50.4%
19.4%
Q1 25
50.8%
19.1%
Q4 24
56.3%
19.2%
Q3 24
52.6%
20.3%
Q2 24
54.0%
19.2%
Q1 24
56.1%
19.2%
Operating Margin
IART
IART
RXT
RXT
Q4 25
5.3%
-0.5%
Q3 25
2.9%
-5.1%
Q2 25
-123.4%
-3.8%
Q1 25
-4.0%
-5.8%
Q4 24
8.0%
-4.2%
Q3 24
-2.1%
-25.7%
Q2 24
-0.7%
-7.9%
Q1 24
1.1%
-94.5%
Net Margin
IART
IART
RXT
RXT
Q4 25
-4.8%
Q3 25
-1.3%
-10.0%
Q2 25
-116.5%
-8.2%
Q1 25
-6.6%
-10.7%
Q4 24
-8.2%
Q3 24
-2.8%
-27.6%
Q2 24
-3.0%
3.7%
Q1 24
-0.9%
-92.7%
EPS (diluted)
IART
IART
RXT
RXT
Q4 25
$-0.03
$-0.13
Q3 25
$-0.07
$-0.28
Q2 25
$-6.31
$-0.23
Q1 25
$-0.33
$-0.31
Q4 24
$0.25
$-0.20
Q3 24
$-0.14
$-0.82
Q2 24
$-0.16
$0.11
Q1 24
$-0.04
$-2.91

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IART
IART
RXT
RXT
Cash + ST InvestmentsLiquidity on hand
$263.7M
$105.8M
Total DebtLower is stronger
$726.6M
$2.7B
Stockholders' EquityBook value
$1.0B
$-1.2B
Total Assets
$3.6B
$2.8B
Debt / EquityLower = less leverage
0.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IART
IART
RXT
RXT
Q4 25
$263.7M
$105.8M
Q3 25
$267.9M
$99.5M
Q2 25
$253.6M
$103.9M
Q1 25
$273.3M
$128.0M
Q4 24
$273.6M
$144.0M
Q3 24
$277.6M
$157.1M
Q2 24
$296.9M
$190.2M
Q1 24
$663.1M
$282.6M
Total Debt
IART
IART
RXT
RXT
Q4 25
$726.6M
$2.7B
Q3 25
$736.3M
$2.8B
Q2 25
$745.9M
$2.8B
Q1 25
$755.6M
$2.8B
Q4 24
$760.5M
$2.8B
Q3 24
$765.3M
$2.8B
Q2 24
$770.2M
$2.9B
Q1 24
$775.0M
$3.0B
Stockholders' Equity
IART
IART
RXT
RXT
Q4 25
$1.0B
$-1.2B
Q3 25
$1.0B
$-1.2B
Q2 25
$1.0B
$-1.1B
Q1 25
$1.5B
$-1.1B
Q4 24
$1.5B
$-1.0B
Q3 24
$1.5B
$-949.7M
Q2 24
$1.5B
$-756.2M
Q1 24
$1.6B
$-787.2M
Total Assets
IART
IART
RXT
RXT
Q4 25
$3.6B
$2.8B
Q3 25
$3.6B
$2.8B
Q2 25
$3.7B
$2.9B
Q1 25
$4.1B
$3.0B
Q4 24
$4.0B
$3.1B
Q3 24
$4.1B
$3.1B
Q2 24
$4.1B
$3.4B
Q1 24
$4.1B
$3.5B
Debt / Equity
IART
IART
RXT
RXT
Q4 25
0.70×
Q3 25
0.71×
Q2 25
0.72×
Q1 25
0.50×
Q4 24
0.49×
Q3 24
0.50×
Q2 24
0.50×
Q1 24
0.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IART
IART
RXT
RXT
Operating Cash FlowLast quarter
$11.8M
$59.7M
Free Cash FlowOCF − Capex
$-5.4M
$56.0M
FCF MarginFCF / Revenue
-1.2%
8.2%
Capex IntensityCapex / Revenue
4.0%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-31.1M
$90.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IART
IART
RXT
RXT
Q4 25
$11.8M
$59.7M
Q3 25
$40.9M
$70.7M
Q2 25
$8.9M
$8.4M
Q1 25
$-11.3M
$12.6M
Q4 24
$50.7M
$54.3M
Q3 24
$22.5M
$51.8M
Q2 24
$40.4M
$24.1M
Q1 24
$15.8M
$-90.3M
Free Cash Flow
IART
IART
RXT
RXT
Q4 25
$-5.4M
$56.0M
Q3 25
$25.8M
$42.7M
Q2 25
$-11.2M
$-12.4M
Q1 25
$-40.2M
$4.3M
Q4 24
$21.1M
$34.4M
Q3 24
$-7.2M
$27.3M
Q2 24
$10.7M
$-14.5M
Q1 24
$291.0K
$-118.4M
FCF Margin
IART
IART
RXT
RXT
Q4 25
-1.2%
8.2%
Q3 25
6.4%
6.4%
Q2 25
-2.7%
-1.9%
Q1 25
-10.5%
0.6%
Q4 24
4.8%
5.0%
Q3 24
-1.9%
4.0%
Q2 24
2.6%
-2.1%
Q1 24
0.1%
-17.1%
Capex Intensity
IART
IART
RXT
RXT
Q4 25
4.0%
0.5%
Q3 25
3.8%
4.2%
Q2 25
4.8%
3.1%
Q1 25
7.6%
1.2%
Q4 24
6.7%
2.9%
Q3 24
7.8%
3.6%
Q2 24
7.1%
5.6%
Q1 24
4.2%
4.1%
Cash Conversion
IART
IART
RXT
RXT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.96×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IART
IART

Neurosurgery$226.2M52%
Asia Pacific$53.7M12%
Instruments$52.3M12%
ENT$44.8M10%
Other$38.9M9%
Rest Of The World$19.0M4%

RXT
RXT

Public Cloud Services Segment$442.2M65%
Private Cloud Service Segment$240.6M35%

Related Comparisons